NCCN GuidelinesĀ®: Insights malignant pleural mesothelioma, version 3.2016 Article Report uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lung Neoplasms
  • Lymphoma, Large-Cell, Anaplastic

abstract

  • These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

authors

publication date

  • July 2016

Research

keywords

  • Report

Identity

PubMed ID

  • 27407123

Additional Document Info

start page

  • 825

end page

  • 36

volume

  • 14

number

  • 7